FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072057417> ?p ?o ?g. }

• W2072057417 endingPage "58" @default.
• W2072057417 startingPage "53" @default.
• W2072057417 abstract "SDZ RAD (everolimus, Certican™) is a novel macrolide immunosuppressant that blocks growth factor-driven transduction signals in the T-cell response to alloantigen. After stimulation of the IL-2 receptor on the activated T-cell, SDZ RAD inhibits p70S6 kinase, acting at a later stage in the T-cell mediated response than do cyclosporine and other calcineurin inhibitors (CNIs). Unlike the CNIs, SDZ RAD is a proliferation signal inhibitor, blocking growth factor-driven proliferation of both hematopoietic and nonhematopoietic cells. These activities are complementary to those of cyclosporine and provide a rationale for the addition of SDZ RAD to cyclosporine-based immunosuppression, with the potential for minimizing CNI nephrotoxicity, reducing the incidence of acute rejection, and favoring long-term graft survival. Potential also exists for beneficial effects on other factors that may influence the development of chronic rejection. These factors include comorbid diseases such as hypertension, which may affect transplant vasculopathy, and opportunistic infection with cytomegalovirus (CMV) and other viruses, which may increase the risk of chronic rejection. The synergistic effect of SDZ RAD and cyclosporine has been confirmed in preclinical models, with graft survival being significantly prolonged in rat models of kidney and heart allotransplantation. Clinical experience with SDZ RAD in cyclosporine-based immunosuppression, including low-dose cyclosporine regimens, has also resulted in predictable and favorable clinical outcomes. Low rates of acute rejection, excellent rates of patient and graft survival, lower incidence of CMV infections, better cholesterol, triglyceride and creatinine profiles, and better renal function have been demonstrated with SDZ RAD and lower doses of cyclosporine (Neoral; Novartis Pharmaceuticals, East Hanover, NJ) in recipients of renal transplants. These findings, combined with good tolerability rates and an acceptable side-effect profile, indicate that the synergistic profile of SDZ RAD in combination with nontoxic dosages of CNI's and IL2 inhibitors will further improve longterm results in renal transplantation." @default.
• W2072057417 created "2016-06-24" @default.
• W2072057417 creator A5044825904 @default.
• W2072057417 date "2002-02-01" @default.
• W2072057417 modified "2023-10-14" @default.
• W2072057417 title "Early Clinical Experience With a Novel Rapamycin Derivative" @default.
• W2072057417 cites W1756759934 @default.
• W2072057417 cites W1964317460 @default.
• W2072057417 cites W1968322113 @default.
• W2072057417 cites W1973091323 @default.
• W2072057417 cites W1980161688 @default.
• W2072057417 cites W1985137297 @default.
• W2072057417 cites W1988037390 @default.
• W2072057417 cites W1998826311 @default.
• W2072057417 cites W2008800889 @default.
• W2072057417 cites W2014170114 @default.
• W2072057417 cites W2018523148 @default.
• W2072057417 cites W2021142445 @default.
• W2072057417 cites W2023342293 @default.
• W2072057417 cites W2024700631 @default.
• W2072057417 cites W2025186886 @default.
• W2072057417 cites W2027371366 @default.
• W2072057417 cites W2028549543 @default.
• W2072057417 cites W2045308409 @default.
• W2072057417 cites W2047140243 @default.
• W2072057417 cites W2053652471 @default.
• W2072057417 cites W2059485285 @default.
• W2072057417 cites W2061318236 @default.
• W2072057417 cites W2084108198 @default.
• W2072057417 cites W2089062413 @default.
• W2072057417 cites W2093979277 @default.
• W2072057417 cites W2098173664 @default.
• W2072057417 cites W2099400944 @default.
• W2072057417 cites W2099890709 @default.
• W2072057417 cites W2123720448 @default.
• W2072057417 cites W2129105507 @default.
• W2072057417 cites W2134930343 @default.
• W2072057417 cites W2137957237 @default.
• W2072057417 cites W2154971806 @default.
• W2072057417 cites W2163813322 @default.
• W2072057417 cites W2168622550 @default.
• W2072057417 cites W4230996310 @default.
• W2072057417 cites W4254973118 @default.
• W2072057417 cites W68282923 @default.
• W2072057417 doi "https://doi.org/10.1097/00007691-200202000-00010" @default.
• W2072057417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11805723" @default.
• W2072057417 hasPublicationYear "2002" @default.
• W2072057417 type Work @default.
• W2072057417 sameAs 2072057417 @default.
• W2072057417 citedByCount "72" @default.
• W2072057417 countsByYear W20720574172012 @default.
• W2072057417 countsByYear W20720574172013 @default.
• W2072057417 countsByYear W20720574172014 @default.
• W2072057417 countsByYear W20720574172015 @default.
• W2072057417 countsByYear W20720574172016 @default.
• W2072057417 countsByYear W20720574172020 @default.
• W2072057417 countsByYear W20720574172021 @default.
• W2072057417 countsByYear W20720574172022 @default.
• W2072057417 crossrefType "journal-article" @default.
• W2072057417 hasAuthorship W2072057417A5044825904 @default.
• W2072057417 hasConcept C126189478 @default.
• W2072057417 hasConcept C126322002 @default.
• W2072057417 hasConcept C126894567 @default.
• W2072057417 hasConcept C128057223 @default.
• W2072057417 hasConcept C159641895 @default.
• W2072057417 hasConcept C2777921159 @default.
• W2072057417 hasConcept C2778653478 @default.
• W2072057417 hasConcept C2779699572 @default.
• W2072057417 hasConcept C2780091579 @default.
• W2072057417 hasConcept C2780252810 @default.
• W2072057417 hasConcept C2780303639 @default.
• W2072057417 hasConcept C2911091166 @default.
• W2072057417 hasConcept C71924100 @default.
• W2072057417 hasConcept C98274493 @default.
• W2072057417 hasConceptScore W2072057417C126189478 @default.
• W2072057417 hasConceptScore W2072057417C126322002 @default.
• W2072057417 hasConceptScore W2072057417C126894567 @default.
• W2072057417 hasConceptScore W2072057417C128057223 @default.
• W2072057417 hasConceptScore W2072057417C159641895 @default.
• W2072057417 hasConceptScore W2072057417C2777921159 @default.
• W2072057417 hasConceptScore W2072057417C2778653478 @default.
• W2072057417 hasConceptScore W2072057417C2779699572 @default.
• W2072057417 hasConceptScore W2072057417C2780091579 @default.
• W2072057417 hasConceptScore W2072057417C2780252810 @default.
• W2072057417 hasConceptScore W2072057417C2780303639 @default.
• W2072057417 hasConceptScore W2072057417C2911091166 @default.
• W2072057417 hasConceptScore W2072057417C71924100 @default.
• W2072057417 hasConceptScore W2072057417C98274493 @default.
• W2072057417 hasIssue "1" @default.
• W2072057417 hasLocation W20720574171 @default.
• W2072057417 hasLocation W20720574172 @default.
• W2072057417 hasOpenAccess W2072057417 @default.
• W2072057417 hasPrimaryLocation W20720574171 @default.
• W2072057417 hasRelatedWork W150091706 @default.
• W2072057417 hasRelatedWork W1777221585 @default.
• W2072057417 hasRelatedWork W2024790512 @default.
• W2072057417 hasRelatedWork W2030500599 @default.
• W2072057417 hasRelatedWork W2130219955 @default.

• next